LU92642I2 - Pomalidomide et ses sels, solvates, hydrates ou stéréoisomères pharmaceutiquement acceptables qui endérivent (Imnovid) - Google Patents

Pomalidomide et ses sels, solvates, hydrates ou stéréoisomères pharmaceutiquement acceptables qui endérivent (Imnovid) Download PDF

Info

Publication number: LU92642I2
Authority: LU; Luxembourg
Prior art keywords: methods; endevere; imnovid; pomalidomide; solvates
Prior art date: 2002-05-17

Application number

LU92642C

Other languages

English (en)

French (fr)

Original Assignee

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-17

Filing date

2015-01-27

Publication date

2015-04-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29553516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92642(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-01-27 Application filed by Celgene Corp filed Critical Celgene Corp

2015-04-24 Publication of LU92642I2 publication Critical patent/LU92642I2/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Oncology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Tropical Medicine & Parasitology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Addiction (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)

LU92642C 2002-05-17 2015-01-27 Pomalidomide et ses sels, solvates, hydrates ou stéréoisomères pharmaceutiquement acceptables qui endérivent (Imnovid) LU92642I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US38084202P	2002-05-17	2002-05-17
US42460002P	2002-11-06	2002-11-06
EP03728969A EP1505973B1 (en)	2002-05-17	2003-05-16	Combinations for treating multiple myeloma

Publications (1)

Publication Number	Publication Date
LU92642I2 true LU92642I2 (fr)	2015-04-24

Family

ID=29553516

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU92642C LU92642I2 (fr)	2002-05-17	2015-01-27	Pomalidomide et ses sels, solvates, hydrates ou stéréoisomères pharmaceutiquement acceptables qui endérivent (Imnovid)

Country Status (19)

Country	Link
EP (9)	EP2272513A1 (zh)
JP (8)	JP2005530784A (zh)
KR (2)	KR100793564B1 (zh)
CN (13)	CN103393681B (zh)
AT (1)	ATE459357T1 (zh)
AU (1)	AU2003234626B2 (zh)
CA (10)	CA2727824A1 (zh)
CY (3)	CY1110013T1 (zh)
DE (1)	DE60331537D1 (zh)
DK (1)	DK1505973T3 (zh)
ES (2)	ES2521672T3 (zh)
IL (9)	IL165254A0 (zh)
LU (1)	LU92642I2 (zh)
MX (1)	MXPA04011311A (zh)
NZ (5)	NZ572388A (zh)
PT (2)	PT1505973E (zh)
SI (1)	SI1505973T1 (zh)
WO (1)	WO2003097052A2 (zh)
ZA (3)	ZA200503656B (zh)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU228769B1 (en)	1996-07-24	2013-05-28	Celgene Corp	Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
JP4361273B2 (ja)	2001-02-27	2009-11-11	アメリカ合衆国	潜在的な血管形成阻害剤としてのサリドマイド類似体
US7323479B2 (en) *	2002-05-17	2008-01-29	Celgene Corporation	Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
EP2272513A1 (en) *	2002-05-17	2011-01-12	Celgene Corporation	Pharmaceutical compositions for treating cancer
US7393862B2 (en)	2002-05-17	2008-07-01	Celgene Corporation	Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US8404716B2 (en)	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en)	2002-10-15	2021-09-14	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7189740B2 (en)	2002-10-15	2007-03-13	Celgene Corporation	Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
JP2006508950A (ja) *	2002-10-31	2006-03-16	セルジーン・コーポレーション	黄斑変性の治療用組成物
US7785601B2 (en) *	2002-12-31	2010-08-31	Sygnis Bioscience Gmbh & Co. Kg	Methods of treating neurological conditions with hematopoietic growth factors
WO2005016326A2 (en) *	2003-07-11	2005-02-24	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Analogs of thalidomide as potential angiogenesis inhibitors
UA83504C2 (en)	2003-09-04	2008-07-25	Селджин Корпорейшн	Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US8952895B2 (en)	2011-06-03	2015-02-10	Apple Inc.	Motion-based device operations
JP4943845B2 (ja)	2003-09-17	2012-05-30	ザガバメントオブザユナイテッドステイツオブアメリカアズリプレゼンティッドバイザセクレタリーオブザデパートメントオブヘルスアンドヒューマンサービシーズ	サリドマイド類似体
US20050100529A1 (en) *	2003-11-06	2005-05-12	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
CN101966183A (zh) *	2003-12-02	2011-02-09	细胞基因公司	用于治疗和控制血红蛋白病和贫血病的方法和组合物
US20050143344A1 (en) *	2003-12-30	2005-06-30	Zeldis Jerome B.	Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
AU2005221283C1 (en)	2004-03-17	2011-02-03	Lars Michael Larsen	Prevention of retinopathy by inhibition of the visual cycle
MXPA06010699A (es) *	2004-03-22	2006-12-15	Celgene Corp	Metodos de usos y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades o alteraciones de la piel.
US20080199422A1 (en) *	2004-04-14	2008-08-21	Celgene Corporation	Method for the Treatment of Myelodysplastic Syndromes Using 1-Oxo-2-(2,6-Dioxopiperidin-3-Yl-)-4-Methylisoindoline
EP1814543A2 (en) *	2004-11-12	2007-08-08	Celgene Corporation	Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
AU2005309733A1 (en) *	2004-11-23	2006-06-01	Celgene Corporation	Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
EP1928492B1 (en) *	2005-09-01	2011-02-23	Celgene Corporation	Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy
WO2007072225A2 (en) *	2005-12-01	2007-06-28	Medical Prognosis Institute	Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
CA2648216C (en)	2006-04-13	2016-06-07	Michael Gutschow	Tetrahalogenated compounds useful as inhibitors of angiogenesis
EP2023912A2 (en) *	2006-05-26	2009-02-18	Celgene Corporation	Methods and compositions using immunomodulatory compounds in combination therapy
CL2007002218A1 (es) *	2006-08-03	2008-03-14	Celgene Corp Soc Organizada Ba	Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
US8632772B2 (en) *	2006-08-07	2014-01-21	Dana-Farber Cancer Institute	Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
JP2010506937A (ja) *	2006-10-19	2010-03-04	セルジーン・コーポレーション	スピロヘータ及びその他の偏性細胞内細菌性疾患の治療及び管理のために免疫調節化合物を用いる方法及び組成物
RU2348420C2 (ru) *	2007-04-17	2009-03-10	ФГУ Ростовский научно-исследовательский онкологический институт Росздрава	Способ лечения местно-распространенного рака легкого
CN101878034B (zh) *	2007-09-28	2013-11-20	细胞基因细胞疗法公司	使用人胎盘灌洗液和人来自胎盘的中间体自然杀伤细胞的肿瘤抑制
UA104579C2 (uk) *	2007-12-10	2014-02-25	Байокрист Фармасьютикалз, Инк.	Спосіб лікування раку кровотворної системи із застосуванням фородезину у комбінації з ритуксимабом
WO2009097120A1 (en) *	2008-01-29	2009-08-06	Celgene Corporation	Methods using immunomodulatory compounds for modulating level of cd59
RU2398525C1 (ru) *	2009-03-25	2010-09-10	Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий"	Способ лечения рака легкого
CN101696205B (zh)	2009-11-02	2011-10-19	南京卡文迪许生物工程技术有限公司	3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
CA2780998C (en) *	2009-11-24	2016-07-12	Celgene Corporation	Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells
SG10202012179RA (en)	2010-02-11	2021-01-28	Celgene Corp	Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
CN103068386A (zh) *	2010-03-12	2013-04-24	细胞基因公司	使用来那度胺治疗非霍奇金淋巴瘤的方法及作为预测因子的基因和蛋白质生物标记
BR112013003169B1 (pt) *	2010-08-18	2022-05-24	Theresa Deisher	Uso de um agente terapêutico que inibe a ligação de células-tronco a tecido linfóide
US10426740B1 (en)	2010-08-18	2019-10-01	Avm Biotechnology, Llc	Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
EP3318253B1 (en) *	2010-11-11	2020-04-22	Ingo Schmidt-Wolf	Compositions comprising wnt inhibitors for treating cancer
US8927725B2 (en)	2011-12-02	2015-01-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Thio compounds
AU2013312188A1 (en) *	2012-09-10	2015-03-26	Celgene Corporation	Methods for the treatment of locally advanced breast cancer
JP6469077B2 (ja) *	2013-04-02	2019-02-13	セルジーンコーポレイション	４−アミノ−２−（２，６−ジオキソ−ピペリジン３−イル）−イソインドリン−１，３−ジオンを使用する中枢神経の癌の治療及び管理のための方法及び組成物
GB201322626D0 (en) *	2013-12-19	2014-02-05	Immutep S A	Combined preparations for the treatment of cancer
CN104231068A (zh) *	2014-01-27	2014-12-24	苏州发士达生物科技有限公司	人白细胞介素ii突变体及其应用
JP6616934B2 (ja) *	2014-05-22	2019-12-04	株式会社資生堂	レナリドミドの光学分割方法
US10034872B2 (en)	2014-08-22	2018-07-31	Celgene Corporation	Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
US10570457B2 (en)	2014-09-26	2020-02-25	Medical Prognosis Institute A/S	Methods for predicting drug responsiveness
GB201500374D0 (en)	2015-01-09	2015-02-25	Immutep S A	Combined preparations for the treatment of cancer
CN107249502A (zh) *	2015-01-20	2017-10-13	斯里瓦特桑·拉加万	自照明式面颊牵开器
CN108366987A (zh)	2015-04-30	2018-08-03	河谷控股Ip有限责任公司	通过致畸药物化合物对患者进行治疗
CA2990478A1 (en) *	2015-06-29	2017-01-05	Bristol-Myers Squibb Company	Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer
WO2017070606A1 (en) *	2015-10-21	2017-04-27	Teclison Limited	Compositions and methods for immune-mediated cancer therapy
CN105388237B (zh) *	2015-12-28	2017-02-01	成都百裕金阁莱药业有限公司	阿普斯特中3‑乙酰氨基邻苯二甲酸的检测方法
US9725769B1 (en)	2016-10-07	2017-08-08	Oncology Venture ApS	Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en)	2016-12-30	2018-07-19	Allarity Therapeutics Europe ApS	Methods for predicting drug responsiveness in cancer patients
CA3050309A1 (en)	2017-01-31	2018-08-09	Arvinas Operations, Inc.	Cereblon ligands and bifunctional compounds comprising the same
CA3054443A1 (en)	2017-04-01	2018-10-14	Avm Biotechnology, Llc	Replacement of cytotoxic preconditioning before cellular immunotherapy
MX2019014023A (es)	2017-05-24	2020-02-17	Novartis Ag	Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
WO2019081749A1 (en) *	2017-10-26	2019-05-02	Synbias Pharma Ag	IMMEDIATE RELEASE FORMULATIONS OF LENALIDOMIDE
SI3784663T1 (sl)	2018-04-23	2023-11-30	Celgene Corporation	Spojine substituiranega 4-aminoizoindolin-1,3-diona in njihova uporaba za zdravljenje limfoma
BR112020023756A2 (pt) *	2018-05-23	2021-02-09	Celgene Corporation	tratamento de mieloma múltiplo e uso de biomarcadores para 4-(4-(4-(((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)benzil)piperazin-1-il)-3-fluorobenzonitrila
CN112689627B (zh) *	2018-09-07	2022-03-29	南京明德新药研发有限公司	三环取代哌啶二酮类化合物
EP3488851A1 (en)	2018-10-03	2019-05-29	AVM Biotechnology, LLC	Immunoablative therapies
WO2021067546A1 (en) *	2019-10-04	2021-04-08	Dana-Farber Cancer Institute, Inc.	Immunomodulatory imide drugs as zeta-chain-associated protein kinase 70 (zap70) agonists and uses thereof
CN115087448A (zh)	2019-10-21	2022-09-20	新基公司	使用2-(2,6-二氧代哌啶-3-基-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异二氢吲哚-1,3-二酮治疗血液恶性肿瘤的方法
JP7662625B2 (ja) *	2019-10-21	2025-04-15	セルジーンコーポレーション	血液がんの治療方法ならびに２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンに対するコンパニオンバイオマーカーの使用
PE20221582A1 (es)	2019-12-19	2022-10-06	Arvinas Operations Inc	Compuestos y metodos para la degradacion dirigida de receptor de androgenos

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3228601A (en)	1964-02-20	1966-01-11	Monarch Marking Systems Inc	Controls for marking machine
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
US5001116A (en)	1982-12-20	1991-03-19	The Children's Medical Center Corporation	Inhibition of angiogenesis
US4994443A (en)	1982-12-20	1991-02-19	The Children's Medical Center Corporation	Inhibition of angiogenesis
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
US5391485A (en)	1985-08-06	1995-02-21	Immunex Corporation	DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en)	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja)	1985-08-23	1988-03-10	麒麟麦酒株式会社	多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US5073543A (en)	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it)	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en)	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en)	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5360352A (en)	1992-12-24	1994-11-01	The Whitaker Corporation	Wire retainer for current mode coupler
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
US5629327A (en)	1993-03-01	1997-05-13	Childrens Hospital Medical Center Corp.	Methods and compositions for inhibition of angiogenesis
US6114355A (en)	1993-03-01	2000-09-05	D'amato; Robert	Methods and compositions for inhibition of angiogenesis
US5698579A (en)	1993-07-02	1997-12-16	Celgene Corporation	Cyclic amides
IT1270594B (it)	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5798368A (en)	1996-08-22	1998-08-25	Celgene Corporation	Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US5635517B1 (en)	1996-07-24	1999-06-29	Celgene Corp	Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
EP1285916B1 (en)	1996-07-24	2010-03-10	Celgene Corporation	Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNF alpha levels
US6281230B1 (en)	1996-07-24	2001-08-28	Celgene Corporation	Isoindolines, method of use, and pharmaceutical compositions
HU228769B1 (en)	1996-07-24	2013-05-28	Celgene Corp	Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
EP0918746B1 (en)	1996-08-12	2003-04-09	Celgene Corporation	Immunotherapeutic agents and their use in the reduction of cytokine levels
ES2253787T3 (es) *	1996-11-05	2006-06-01	The Children's Medical Center Corporation	Composiciones para inhibicion de la angiogenesis que comprenden talidomida y un nsaid.
US5874448A (en)	1997-11-18	1999-02-23	Celgene Corporation	Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US6020358A (en) *	1998-10-30	2000-02-01	Celgene Corporation	Substituted phenethylsulfones and method of reducing TNFα levels
ATE442839T1 (de) *	1999-04-01	2009-10-15	Hana Biosciences Inc	Zusammensetzungen und methoden zur behandlung lymphoma
CN1429121A (zh) *	2000-03-17	2003-07-09	细胞治疗公司	聚谷氨酸－喜树碱结合物及其制备方法
KR100790589B1 (ko) *	2000-05-15	2008-01-02	셀겐코포레이션	암 치료용 조성물 및 치료 방법
US6458810B1 (en) *	2000-11-14	2002-10-01	George Muller	Pharmaceutically active isoindoline derivatives
CA2430669C (en) *	2000-11-30	2011-06-14	The Children's Medical Center Corporation	Synthesis of 3-amino-thalidomide and its enantiomers
US20030045552A1 (en)	2000-12-27	2003-03-06	Robarge Michael J.	Isoindole-imide compounds, compositions, and uses thereof
US7323479B2 (en) *	2002-05-17	2008-01-29	Celgene Corporation	Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
EP2272513A1 (en)	2002-05-17	2011-01-12	Celgene Corporation	Pharmaceutical compositions for treating cancer

2003
- 2003-05-16 EP EP10177056A patent/EP2272513A1/en not_active Withdrawn
- 2003-05-16 IL IL16525403A patent/IL165254A0/xx unknown
- 2003-05-16 CA CA2727824A patent/CA2727824A1/en not_active Abandoned
- 2003-05-16 NZ NZ572388A patent/NZ572388A/en not_active IP Right Cessation
- 2003-05-16 MX MXPA04011311A patent/MXPA04011311A/es active IP Right Grant
- 2003-05-16 EP EP09004756A patent/EP2087891A3/en not_active Withdrawn
- 2003-05-16 CN CN201310344594.3A patent/CN103393681B/zh not_active Expired - Lifetime
- 2003-05-16 NZ NZ563281A patent/NZ563281A/en not_active IP Right Cessation
- 2003-05-16 KR KR1020047018587A patent/KR100793564B1/ko not_active Expired - Lifetime
- 2003-05-16 NZ NZ536907A patent/NZ536907A/en not_active IP Right Cessation
- 2003-05-16 WO PCT/US2003/015470 patent/WO2003097052A2/en not_active Ceased
- 2003-05-16 KR KR1020067020849A patent/KR100822149B1/ko not_active Expired - Fee Related
- 2003-05-16 CA CA2476983A patent/CA2476983C/en not_active Expired - Lifetime
- 2003-05-16 SI SI200331793T patent/SI1505973T1/sl unknown
- 2003-05-16 CN CN2011102566053A patent/CN102302494A/zh active Pending
- 2003-05-16 CN CN201310343756.1A patent/CN103495169B/zh not_active Expired - Lifetime
- 2003-05-16 CA CA2752140A patent/CA2752140A1/en not_active Abandoned
- 2003-05-16 CN CN201310344609.6A patent/CN103494817A/zh not_active Withdrawn
- 2003-05-16 CN CN2013103449770A patent/CN103393695A/zh not_active Withdrawn
- 2003-05-16 ES ES09008756.0T patent/ES2521672T3/es not_active Expired - Lifetime
- 2003-05-16 AT AT03728969T patent/ATE459357T1/de active
- 2003-05-16 CA CA2727830A patent/CA2727830C/en not_active Expired - Lifetime
- 2003-05-16 CA CA2794060A patent/CA2794060C/en not_active Expired - Lifetime
- 2003-05-16 CN CN201110256752.0A patent/CN102379874B/zh not_active Expired - Lifetime
- 2003-05-16 EP EP12158938.6A patent/EP2561874A3/en not_active Withdrawn
- 2003-05-16 CA CA2752124A patent/CA2752124A1/en not_active Abandoned
- 2003-05-16 EP EP10185504A patent/EP2316455A1/en not_active Withdrawn
- 2003-05-16 CA CA2752127A patent/CA2752127A1/en not_active Abandoned
- 2003-05-16 DK DK03728969.1T patent/DK1505973T3/da active
- 2003-05-16 CA CA2672000A patent/CA2672000C/en not_active Expired - Lifetime
- 2003-05-16 CN CN2011102571780A patent/CN102429908A/zh active Pending
- 2003-05-16 NZ NZ549175A patent/NZ549175A/en not_active IP Right Cessation
- 2003-05-16 CN CN201110257161.5A patent/CN102342938B/zh not_active Expired - Lifetime
- 2003-05-16 EP EP03728969A patent/EP1505973B1/en not_active Revoked
- 2003-05-16 EP EP09008756.0A patent/EP2105135B1/en not_active Revoked
- 2003-05-16 EP EP10177041A patent/EP2272512A1/en not_active Withdrawn
- 2003-05-16 CN CN2006101504843A patent/CN1981761B/zh not_active Expired - Fee Related
- 2003-05-16 JP JP2004505051A patent/JP2005530784A/ja active Pending
- 2003-05-16 PT PT03728969T patent/PT1505973E/pt unknown
- 2003-05-16 CN CN2011102561581A patent/CN102335173A/zh active Pending
- 2003-05-16 CA CA2794297A patent/CA2794297A1/en not_active Abandoned
- 2003-05-16 EP EP09008775A patent/EP2105136A3/en not_active Withdrawn
- 2003-05-16 CN CN038168995A patent/CN1697655B/zh not_active Expired - Lifetime
- 2003-05-16 DE DE60331537T patent/DE60331537D1/de not_active Expired - Lifetime
- 2003-05-16 CN CN201410690665.XA patent/CN104606193A/zh not_active Withdrawn
- 2003-05-16 EP EP14189022.8A patent/EP2915533B1/en not_active Revoked
- 2003-05-16 NZ NZ584663A patent/NZ584663A/en not_active IP Right Cessation
- 2003-05-16 AU AU2003234626A patent/AU2003234626B2/en not_active Expired
- 2003-05-16 ES ES03728969T patent/ES2340027T3/es not_active Expired - Lifetime
- 2003-05-16 PT PT90087560T patent/PT2105135E/pt unknown
- 2003-05-16 CA CA2752122A patent/CA2752122A1/en not_active Abandoned
- 2003-11-06 ZA ZA200503656A patent/ZA200503656B/xx unknown
- 2003-11-06 CN CNA2003801083980A patent/CN1735415A/zh active Pending
2004
- 2004-11-16 IL IL165254A patent/IL165254A/en active IP Right Grant
- 2004-11-22 ZA ZA200409388A patent/ZA200409388B/xx unknown
- 2004-11-22 ZA ZA200409387A patent/ZA200409387B/en unknown
2006
- 2006-10-19 IL IL178748A patent/IL178748A/en active IP Right Grant
- 2006-10-19 IL IL178746A patent/IL178746A0/en unknown
- 2006-10-19 IL IL178747A patent/IL178747A/en active IP Right Grant
- 2006-10-19 IL IL178745A patent/IL178745A/en active Protection Beyond IP Right Term
- 2006-10-24 JP JP2006288966A patent/JP2007008966A/ja active Pending
2009
- 2009-05-13 JP JP2009116367A patent/JP5839770B2/ja not_active Expired - Lifetime
- 2009-05-13 JP JP2009116363A patent/JP2009191072A/ja not_active Withdrawn
- 2009-05-26 IL IL198978A patent/IL198978A/en active IP Right Grant
2010
- 2010-04-23 CY CY20101100363T patent/CY1110013T1/el unknown
2012
- 2012-05-10 IL IL219732A patent/IL219732A0/en unknown
- 2012-12-14 JP JP2012273326A patent/JP5830005B2/ja not_active Expired - Lifetime
2013
- 2013-02-28 JP JP2013038222A patent/JP2013126999A/ja not_active Withdrawn
2014
- 2014-11-27 CY CY20141100987T patent/CY1115782T1/el unknown
2015
- 2015-01-27 LU LU92642C patent/LU92642I2/xx unknown
- 2015-02-06 CY CY2015003C patent/CY2015003I2/el unknown
- 2015-06-23 JP JP2015125342A patent/JP6194335B2/ja not_active Expired - Lifetime
2016
- 2016-03-22 IL IL244727A patent/IL244727A0/en unknown
2017
- 2017-05-12 JP JP2017095838A patent/JP2017132817A/ja active Pending

Also Published As

Publication number	Publication date
EP2272512A1 (en)	2011-01-12
CN102379874B (zh)	2016-08-17
ZA200503656B (en)	2009-02-25
CN103393681A (zh)	2013-11-20
IL178745A0 (en)	2007-02-11
EP2915533A1 (en)	2015-09-09
CN102335173A (zh)	2012-02-01
EP1505973B1 (en)	2010-03-03
CN103393695A (zh)	2013-11-20
CN1697655B (zh)	2013-09-18
CN104606193A (zh)	2015-05-13
CY2015003I1 (el)	2015-12-09
ES2340027T3 (es)	2010-05-28
JP2009173683A (ja)	2009-08-06
AU2003234626A1 (en)	2003-12-02
JP5830005B2 (ja)	2015-12-09
KR20060110014A (ko)	2006-10-23
CA2752122A1 (en)	2003-11-27
JP2007008966A (ja)	2007-01-18
IL178747A0 (en)	2007-02-11
CA2672000A1 (en)	2003-11-27
JP5839770B2 (ja)	2016-01-06
IL178746A0 (en)	2007-02-11
CY2015003I2 (el)	2015-12-09
DE60331537D1 (de)	2010-04-15
EP1505973A4 (en)	2006-05-17
JP2015187156A (ja)	2015-10-29
IL165254A0 (en)	2005-12-18
CY1115782T1 (el)	2015-12-09
IL178745A (en)	2012-06-28
NZ584663A (en)	2011-09-30
IL178748A0 (en)	2007-02-11
CA2727824A1 (en)	2003-11-27
IL165254A (en)	2013-03-24
CN103494817A (zh)	2014-01-08
CY1110013T1 (el)	2015-01-14
JP2009191072A (ja)	2009-08-27
HK1134019A1 (zh)	2010-04-16
NZ549175A (en)	2007-12-21
EP2316455A1 (en)	2011-05-04
KR20050010815A (ko)	2005-01-28
IL198978A (en)	2011-08-31
ZA200409387B (en)	2006-06-28
EP2561874A2 (en)	2013-02-27
IL178747A (en)	2015-06-30
CN1697655A (zh)	2005-11-16
EP2105135A3 (en)	2010-02-10
NZ572388A (en)	2010-05-28
AU2003234626C1 (en)	2003-12-02
EP2087891A2 (en)	2009-08-12
CN102429908A (zh)	2012-05-02
HK1072180A1 (zh)	2005-08-19
CA2752140A1 (en)	2003-11-27
WO2003097052A2 (en)	2003-11-27
KR100822149B1 (ko)	2008-04-15
CA2794060A1 (en)	2003-11-27
CN102342938B (zh)	2014-08-20
MXPA04011311A (es)	2005-02-14
CA2727830C (en)	2014-09-16
CA2794060C (en)	2017-08-22
EP2105135A2 (en)	2009-09-30
SI1505973T1 (sl)	2010-06-30
CA2752127A1 (en)	2003-11-27
JP2013049734A (ja)	2013-03-14
ZA200409388B (en)	2006-05-31
EP2087891A3 (en)	2010-01-27
NZ563281A (en)	2009-05-31
KR100793564B1 (ko)	2008-01-14
EP2105136A2 (en)	2009-09-30
IL178748A (en)	2013-10-31
CN1981761A (zh)	2007-06-20
EP2105136A3 (en)	2010-01-27
CN1735415A (zh)	2006-02-15
HK1104968A1 (zh)	2008-02-01
CA2752124A1 (en)	2003-11-27
EP1505973A2 (en)	2005-02-16
NZ536907A (en)	2006-10-27
ES2521672T3 (es)	2014-11-13
CN1981761B (zh)	2011-10-12
PT1505973E (pt)	2010-05-21
IL244727A0 (en)	2016-05-01
EP2272513A1 (en)	2011-01-12
EP2915533B1 (en)	2017-09-13
CA2727830A1 (en)	2003-11-27
CN103495169B (zh)	2016-06-22
CA2672000C (en)	2011-11-29
CN102379874A (zh)	2012-03-21
CN102302494A (zh)	2012-01-04
DK1505973T3 (da)	2010-05-31
JP6194335B2 (ja)	2017-09-06
JP2017132817A (ja)	2017-08-03
CA2794297A1 (en)	2003-11-27
CN103495169A (zh)	2014-01-08
CA2476983C (en)	2011-01-25
EP2561874A3 (en)	2013-09-04
PT2105135E (pt)	2015-02-06
JP2005530784A (ja)	2005-10-13
WO2003097052A3 (en)	2003-12-18
IL219732A0 (en)	2012-06-28
CN102342938A (zh)	2012-02-08
CA2476983A1 (en)	2003-11-27
ATE459357T1 (de)	2010-03-15
EP2105135B1 (en)	2014-10-22
CN103393681B (zh)	2017-04-12
AU2003234626B2 (en)	2006-03-09
JP2013126999A (ja)	2013-06-27

Publication	Publication Date	Title
LU92642I2 (fr)	2015-04-24	Pomalidomide et ses sels, solvates, hydrates ou stéréoisomères pharmaceutiquement acceptables qui endérivent (Imnovid)
TW200500355A (en)	2005-01-01	Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
MXPA05012155A (es)	2006-02-22	Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
MX2007005570A (es)	2007-07-09	Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y manejo de padecimientos parasiticos.
WO2005046593A3 (en)	2006-03-02	Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
ATE411022T1 (de)	2008-10-15	Pyridylpyrrol-derivate als wirksame kinase-hemmer
WO2005046318A3 (en)	2007-06-21	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
NO20062504L (no)	2006-07-21	Sammensetninger og doseringsformer for forbedret absorpsjon
TW200501945A (en)	2005-01-16	Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
MX2021008010A (es)	2021-10-13	Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld).
CO5190664A1 (es)	2002-08-29	Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
BR0017120A (pt)	2003-01-14	Composição farmacêutica
DE60221104D1 (de)	2007-08-23	Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
ZA202311007B (en)	2025-08-27	Organotrisulfide and organotetrasulfide compounds and the use thereof in methods of treatment
BRPI0509240A (pt)	2007-09-04	regime de tratamento para derivados de camptotecina
AR033579A1 (es)	2003-12-26	Terapia antitumoral que comprende derivados de distamicina